Logo image of SPRC

SCISPARC LTD (SPRC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SPRC - IL0010951403 - Common Stock

1.46 USD
-0.05 (-3.31%)
Last: 1/9/2026, 8:27:47 PM
1.4344 USD
-0.03 (-1.75%)
After Hours: 1/9/2026, 8:27:47 PM
Fundamental Rating

0

SPRC gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SPRC have multiple concerns. SPRC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SPRC has reported negative net income.
SPRC had negative earnings in each of the past 5 years.
SPRC had a negative operating cash flow in each of the past 5 years.
SPRC Yearly Net Income VS EBIT VS OCF VS FCFSPRC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

SPRC has a Return On Assets of -122.18%. This is amonst the worse of the industry: SPRC underperforms 81.15% of its industry peers.
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROIC N/A
ROA(3y)-44.59%
ROA(5y)-65.61%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
SPRC Yearly ROA, ROE, ROICSPRC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

1.3 Margins

SPRC's Gross Margin of 38.74% is fine compared to the rest of the industry. SPRC outperforms 61.26% of its industry peers.
SPRC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRC Yearly Profit, Operating, Gross MarginsSPRC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

SPRC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRC has more shares outstanding
SPRC has more shares outstanding than it did 5 years ago.
SPRC has a better debt/assets ratio than last year.
SPRC Yearly Shares OutstandingSPRC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRC Yearly Total Debt VS Total AssetsSPRC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

SPRC has an Altman-Z score of -23.23. This is a bad value and indicates that SPRC is not financially healthy and even has some risk of bankruptcy.
SPRC's Altman-Z score of -23.23 is on the low side compared to the rest of the industry. SPRC is outperformed by 86.39% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.23
ROIC/WACCN/A
WACC8.65%
SPRC Yearly LT Debt VS Equity VS FCFSPRC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

SPRC has a Current Ratio of 0.55. This is a bad value and indicates that SPRC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.55, SPRC is doing worse than 91.10% of the companies in the same industry.
SPRC has a Quick Ratio of 0.55. This is a bad value and indicates that SPRC is not financially healthy enough and could expect problems in meeting its short term obligations.
SPRC has a worse Quick ratio (0.52) than 89.53% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.52
SPRC Yearly Current Assets VS Current LiabilitesSPRC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

SPRC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.42%, which is quite impressive.
The Revenue for SPRC has decreased by -54.64% in the past year. This is quite bad
EPS 1Y (TTM)91.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRC Yearly Revenue VS EstimatesSPRC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SPRC Yearly EPS VS EstimatesSPRC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRC Price Earnings VS Forward Price EarningsSPRC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRC Per share dataSPRC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SPRC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SCISPARC LTD

NASDAQ:SPRC (1/9/2026, 8:27:47 PM)

After market: 1.4344 -0.03 (-1.75%)

1.46

-0.05 (-3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24 2025-04-24
Earnings (Next)N/A N/A
Inst Owners0.24%
Inst Owner Change0%
Ins Owners26.3%
Ins Owner ChangeN/A
Market Cap4.79M
Revenue(TTM)1.31M
Net Income(TTM)-6.28M
AnalystsN/A
Price TargetN/A
Short Float %1.76%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.63
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.4
BVpS-0.24
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.74%
FCFM N/A
ROA(3y)-44.59%
ROA(5y)-65.61%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.52
Altman-Z -23.23
F-ScoreN/A
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.41%
OCF growth 3YN/A
OCF growth 5YN/A

SCISPARC LTD / SPRC FAQ

Can you provide the ChartMill fundamental rating for SCISPARC LTD?

ChartMill assigns a fundamental rating of 0 / 10 to SPRC.


What is the valuation status of SCISPARC LTD (SPRC) stock?

ChartMill assigns a valuation rating of 0 / 10 to SCISPARC LTD (SPRC). This can be considered as Overvalued.


How profitable is SCISPARC LTD (SPRC) stock?

SCISPARC LTD (SPRC) has a profitability rating of 1 / 10.